Robert Varipapa, MD
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,060 of the $2,977 with a category attached, or 69.2%. 19 manufacturers reported payments, led by Livanova USA, Inc. at 46.4% of the total. Reporting peaked in 2023 at $1,723 and has fallen 83.7% since, to $280 in 2025.
Across 66 payments — averaging $45.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$1K
- AbbVie$491
- Medtronic$303
- EMD Serono, Inc.$157
- Novartis$126
- Lilly USA, LLC$111
- plus $408 from 13 others
Across 2 payments — averaging $3396.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$7K
What the payments were for
- Travel & lodging$91631%
- Food & beverage$2,06069%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 6 | $1,380 |
| AbbVie(2 entities) | 24 | $491 |
| Medtronic(2 entities) | 3 | $303 |
| EMD Serono, Inc. | 7 | $157 |
| Novartis | 7 | $126 |
| Lilly USA, LLC | 2 | $111 |
| Penumbra, Inc. | 1 | $87 |
| Biogen | 3 | $55 |
| Amneal Pharmaceuticals LLC | 2 | $48 |
| Life Molecular Imaging Ltd | 1 | $48 |
| Bristol Myers Squibb | 2 | $28 |
| Insightec,inc | 1 | $27 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Pfizer | 1 | $22 |
| Sanofi | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Grifols USA, LLC | 1 | $13 |
| Sumitomo Pharma America, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,380
- INTELLIS ADAPTIVESTIM$139
- ACTIVA$102
How this compares
$2,977 in reported general payments places this provider in the 75th percentile of 61 neurology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 57 | $63,867 |
| Aimovig AutoinjectorErenumab-Aooe | 39 | $38,846 |
| Nurtec OdtRimegepant Sulfate | 30 | $28,971 |
| Levetiracetam | 503 | $28,722 |
| Dimethyl Fumarate | 16 | $24,977 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $24,003 |
| Gabapentin | 568 | $16,115 |
| FycompaPerampanel | 14 | $15,993 |
| Galantamine ErGalantamine Hbr | 132 | $15,583 |
| Lacosamide | 77 | $13,628 |
| Sumatriptan Succinate | 261 | $10,418 |
| Donepezil Hcl | 867 | $9,870 |
| Memantine Hcl | 200 | $8,833 |
| Zonisamide | 340 | $8,265 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 129 | $7,851 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $22 | $28,97130 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $48 | $81512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 61 neurology providers in Delaware.
Other neurology in Dover
- Abraham ScheerDover$231K
- Stephen PennyDover$2K
- John CollDover$530
- Ahmad SawalhaDover$195
- Ali SheharyarDover$176
- Rakesh JaitlyDover$134
- Joel RutenbergDover$30
- Justin MartelloNewark$485K
- Jason SilversteenNewark$202K
- Jay DaveMilford$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.